glp1medication.guide

Peptides

Weight-loss peptides, sorted by what the evidence actually says

Semaglutide and a vial of retatrutide bought online get called the same thing. They are not the same thing. One has a label, a prescriber and a phase 3 dossier a regulator has read. The other is an unapproved investigational drug copied by an unregulated supplier. These pages keep the tiers separate and put the trial name, dose and duration next to every number.

Nothing here is a source list This cluster names no vendors, no clinics and no telehealth services, and carries no affiliate links. It also carries no dosing, reconstitution or stacking instructions. If you want to use any compound on these pages, that conversation belongs with a prescriber.

Peptides for Weight Loss: A Tiered Guide to What Is Approved, Pipeline, and Grey Market

The triage page. Place any compound name into one of three tiers in seconds, with the best trial number and the legal position attached.

Retatrutide: Triple Agonist Phase 3 Results and Current Status

The strongest weight-loss numbers in obesity medicine, attached to a drug you cannot legally obtain.

GLP-3 Peptide: There Is No Such Drug, and What the Search Really Means

A term invented by the market, answered by nobody who is not selling something.

Cagrilintide and CagriSema: The Amylin Route to Weight Loss

A genuinely different mechanism, and a case study in how obesity trial results get framed as wins or misses.

Survodutide: GLP-1/Glucagon Dual Agonist and the Liver-Fat Angle

Mid-pack on weight, distinctive on liver fat. Also a lesson in why a smaller headline percentage does not mean a worse drug.

Mazdutide: Approved in China, Not in the US

The compound that proves the word approved is meaningless without a jurisdiction attached.

Orforglipron: The First Small-Molecule Oral GLP-1 for Weight Management

Lower weight loss than the injectables, and possibly the most consequential approval in the category because of how it is made.

Oral GLP-1 Options Compared: Orforglipron vs Oral Semaglutide 25 mg

The comparison people search for, with the honest caveat that nobody has run the trial that would settle it.

The Next-Generation Obesity Drug Pipeline: Who Is Where

A maintained status board, not an essay. One row per candidate, with a visible review date.

Growth Hormone Peptides and Fat Loss: Tesamorelin, Ipamorelin, CJC-1295, AOD-9604

Four compounds, one shared mechanism story, and one shared evidence problem.

BPC-157: What It Is, What It Is Not, and Its Unsettled Legal Status

A corrective page. The evidence base is tissue repair, the weight-loss listings are a marketing artefact, and the regulatory story is the actual news.

Research-Chemical Peptides: 5-Amino-1MQ and the Grey Market

The consumer-protection page, built around the cleanest example of a compound with everything except human evidence.

Educational content only, not medical advice. Regulatory status and trial results are stated as verified on 23 August 2026 and can change within a quarter. Nothing here is a recommendation to take, buy or stop any drug. Talk to a licensed prescriber about your own situation.

Evidence updates

When a number here changes, you will know